- We kicked off the week with a quick technical blurb about Sarepta Therapeutics, although we didn’t get into the details of our bullish long-term outlook. On Wednesday, Mr. King laid out a little more in regards to the upcoming early filing and explained why SRPT investors should keep some powder dry.
PropThink Premium provides actionable daily trades and research from the experienced team of analysts and traders at PropThink, and you can try it free for 30-days.
- As a trade, Durect shares have gained 10% in the last five days (we covered earnings Monday). But Jason Napodano has been on top of this one since some jarring revelations in November — DRRX has climbed 50% since.
- ISIS’ pipeline and numerous partnerships made for an interesting thesis in December, and the approval of Kynamro helped validate the antisense platform. This week’s breakout has taken gains to nearly 100% from PropThink’s first story.
- The Sefelsa AdComm vote (and approval) was a chancy bet for Depomed investors. Nevertheless, the sell-off has created an entry point. Read why by clicking here, as Mr. Napodano’s model included absolutely no value for the hot flashes treatment.
- ImmunoCellular’s 4Q/YE12 conference call offered clarity on some unresolved issues. The stock is up 34% since PropThink first brought the bullish thesis to the table, and we’re looking for considerably more upside this year.
- The threat of Celgene’s Pomalyst means less for Onyx and Kyprolis than first blush would indicate. And along the lines of commercialization, QCOR is still worth following. Fundamentals are solid, and based on revenue, Mr. King sees fair value in the $40 range.
- Raptor Pharma finally found its bottom last month, as we said. Shares bounced in advance of the upcoming April 30 PDUFA for lead candidate Procysbi and are up 12%.
- Many will be familiar with Affymax’s implosion two weeks ago, but Mr. Deryugin explains why it implies more than just incremental revenue for Amgen. Speaking of, PropThink’s article on the 14th could have saved you from the 80% drop in AFFY.
- Delcath is headed for a positive ODAC vote and FDA approval according to Dr. Chaudhry. She’s done a lot of digging on Special Protocol Assessments (see here), and although DCTH’s technology has only modest prospects in the market, investors should look at the short-term trade.
- Trius Therapeutics is worth mentioning, despite PropThink having been relatively silent on the drug developer since December. Mr. Napodano first covered the company for PropThink in November, which, for investors who got in around that time, has returned 25%. The analyst likes ZLCS as well, and accordingly, updated readers this week.
